Showing results (61-70 of 127) with videos related to

Sort By:
Pageof 13
Frontiers in Immunology|March 13, 2015
Breaking the mold: transcription factors in the anucleate platelet and platelet-derived microparticlesKatie L Lannan, Julie Sahler, Nina Kim, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 19, 2025
State-of-the-Art Review: Hepatitis CVincent Lo Re, Debika Bhattacharya, Jennifer C Price, et al.
Journal of Managed Care & Specialty Pharmacy|July 24, 2025
Real-world patient profile and step-up dosing process of early initiators of teclistamab for multiple myeloma in US hospitals: An analysis using the Premier Healthcare DatabaseCarlyn Rose Tan, Eric Chinaeke, Nina Kim, et al.
AIDS and Behavior|October 16, 2020
Sustained Sobriety: A Qualitative Study of Persons with HIV and Chronic Hepatitis C Coinfection and a History of Problematic DrinkingAbigail Howell, Audrey Lambert, Megan M Pinkston, et al.
Pediatric Rheumatology Online Journal|September 15, 2021
Reasons for canakinumab initiation among patients with periodic fever syndromes: a retrospective medical chart review from the United StatesPeter Hur, Kathleen G Lomax, Raluca Ionescu-Ittu, et al.
Journal of Managed Care & Specialty Pharmacy|August 24, 2022
Health care utilization and costs associated with functional status in patients with psoriatic arthritisAlexis Ogdie, Mark Hwang, Phani Veeranki, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 14, 2014
The specialized proresolving mediator 17-HDHA enhances the antibody-mediated immune response against influenza virus: a new class of adjuvant?Sesquile Ramon, Steven F Baker, Julie M Sahler, et al.
Journal of Palliative Medicine|July 11, 2024
Prognostic Understanding, Goals of Care, and Quality of Life in Hospitalized Patients with Leukemia or Multiple MyelomaSophia Shimer, Olivia S Allen, Chen Yang, et al.
Future Oncology (London, England)|June 5, 2025
Burden of illness among patients with relapsed or refractory multiple myeloma, and eligible for B-cell maturation antigen-targeted therapiesSmith Giri, Dee Lin, Ruth Wangia Dixon, et al.
Current Medical Research and Opinion|May 15, 2024
Panel Interview of ONcology practices with Emergent Experience of teclistamab in the Real world: the TecPIONEER StudyBenjamin A Derman, Meaghan Roach, Dee Lin, et al.
Pageof 13